Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Drug Technical...

    Drug Technical Advisory Board Calls for Hearing on banned 344 FDC drugs, check out details

    Written by Ruby Khatun Khatun Published On 2018-06-03T11:30:11+05:30  |  Updated On 3 Jun 2018 11:30 AM IST
    Drug Technical Advisory Board Calls for Hearing on banned 344 FDC drugs, check out details

    New Delhi: Through a recent public notification, Directorate General of Health Services Office of Drugs Controller General (India) (FDC Division) has invited the applicants for hearing for deliberation by the Sub-committee of DTAB from 5th June 2018 to 22nd June 2018 to examine the banned 344 FDCs + 05 FDCs.


    The Meeting of DTAB sub Committee will be held from 05.06.2018 to 22.06.2018 in the in the office of DCG (I), 1st floor, FDA Bhawan, Kotla Road, Near National Bal Bhawan, New Delhi-110002 to examine the 344 FDCs + 05 FDCs and to provide hearing to the petitioners/appellants.


    The Sub-Committee of DTAB has been constituted under the chairpersonship of Dr. Nilima Kshirsagar, The Chair in Clinical Pharmacology, Indian Council of Medical Research (ICMR) Mumbai, to examine the banned 344 FDCs + 05 FDCs.


    Accordingly, in March through a public notification, CDSCO has requested the petitioners/appellants to submit the information in the prescribed format in hard as well as in soft copy.


    The notice states that in compliance to the directions of Hon'ble Supreme Court of India vide dated 15.12.2017, it has been proposed to give a hearing to all the petitioners/appellants for deliberation by the Sub-committee.


    Accordingly, Sub-Committee invites the concerned applicants for hearing w.e.f. 05.06.2018 to 22.06.2018 w.r.t. FDCs mentioned under annexure A. Date and time of the hearing is also mentioned under annexure A.


    The notice further states that it is requested that the concerned petitioners/appellants may kindly make it convenient to give a presentation before the DTAB Sub Committee on these FDCs. It would be highly appreciated if the presentations are 'to the point' using the PPT (if) already submitted. In the event that the petitioner does not attend the hearing, the Sub-Committee reserves the right to make its decision on the basis of the information before it and according to the direction of Hon'ble Supreme Court.


    The authority has requested the petitioners/appellants to confirm their participation by e-mail at fdcdivision@qmail.com at least 2 days before the scheduled date of the meeting.


    Below is the attachment for the same

    http://www.cdsco.nic.in/writereaddata/websiteupload.pdf
    344 FDC drug banban on FDC drugsBanned 344 FDC drugsDirectorate General of Health ServicesDr Nilima KshirsagarDrugs Controller General of IndiaDTABFDCICMRIndian Council of Medical Researchsub-committeeSupreme Court

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok